Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study
Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study
–PH-762 is Phio's lead product candidate
—PH-762 是 Phio 的主要候选产品
-Screening on the next cohort is on-going
-正在对下一批人进行筛查
MARLBOROUGH, Mass., May 15, 2024 (GLOBE NEWSWIRE) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced progress on its Phase 1b clinical study for their lead compound PH-762. Dosing of the first cohort of patients was completed and screening for the next dose cohort is on-going.
马萨诸塞州马尔伯勒，2024年5月15日（环球新闻专线）——Phio制药公司（纳斯达克股票代码：PHIO）是一家临床阶段的生物技术公司，其专有的INTASYL siRNA基因沉默技术旨在使免疫细胞更有效地杀死肿瘤细胞，今天宣布其主要化合物 PH-762 的1b期临床研究取得进展。第一组患者的给药已经完成，下一个剂量队列的筛查正在进行中。
Phio's Phase 1b study (NCT 06014086) is a multi-center, dose-escalating clinical trial designed to evaluate the safety and tolerability of neoadjuvant use of intratumoral PH-762 in cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma. This study will assess the tumor response, and determine the recommended dose for further study of PH-762.
Phio 的 1b 期研究（NCT 06014086）是一项多中心、剂量递增的临床试验，旨在评估在皮肤鳞状细胞癌、黑色素瘤或默克尔细胞癌中使用肿瘤 PH-762 的新辅助应用的安全性和耐受性。该研究将评估肿瘤反应，并确定进一步研究 PH-762 的推荐剂量。
"This is exciting news for Phio and our lead compound PH-762 with the dosing of the 1st cohort completed, we look forward to advancing the study to bring an innovative treatment option to patients with skin carcinomas," said Robert Bitterman, CEO of Phio Pharmaceuticals.
“对于 Phio 和我们的主要化合物 PH-762 来说，这是个令人振奋的消息，其剂量为 1st 队列已经完成，我们期待推进这项研究，为皮肤癌患者带来创新的治疗选择。” Phio Pharmicals首席执行官罗伯特·比特曼说。
About Phio Pharmaceuticals Corp.
Phio 制药公司简介
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics. INTASYL drugs precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
For additional information, visit the Company's website, www.phiopharma.com.
Phio制药公司（纳斯达克股票代码：PHIO）是一家临床阶段的生物技术公司，其专有的INTASYL siRNA基因沉默技术旨在使免疫细胞更有效地杀死肿瘤细胞。INTASYL 是唯一专注于免疫肿瘤学疗法的自交式 RNAi 技术。INTASYL 药物可精确靶向降低人体抗癌能力的特定蛋白质，无需专门的配方或药物输送系统。
欲了解更多信息，请访问公司的网站， www.phiopharma.com。
Forward Looking Statements
前瞻性陈述
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. These statements are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Examples of forward-looking statements include statements regarding the potential of PH-762 to treat skin carcinomas. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by inflationary pressures, rising interest rates, recession fears, the development of our product candidates, results from our preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.
本新闻稿包含1995年《私人证券诉讼改革法》所指的前瞻性陈述。前瞻性陈述可以通过诸如 “打算”、“相信”、“预期”、“计划”、“预期”、“建议”、“可能”、“将”、“潜在”、“设计用于”、“将”、“持续”、“估计”、“预测”、“目标”、“预测”、“可能” 等词语来识别，尽管不是所有前瞻性陈述包含这些单词。这些陈述仅基于我们当前的信念、预期和假设，并受固有的不确定性、风险和环境变化的影响，这些因素难以预测，其中许多是我们无法控制的。前瞻性陈述的示例包括关于 PH-762 治疗皮肤癌潜力的陈述。由于许多重要因素，我们的实际业绩可能与前瞻性陈述中显示的结果存在重大差异，包括但不限于通货膨胀压力、利率上升、经济衰退担忧、候选产品的开发、临床前和临床活动的结果、我们执行业务战略的能力、我们与合作伙伴开发候选产品的能力以及任何此类合作的成功，时间表和持续时间包括推动我们的候选产品进入临床开发阶段、监管机构申请和批准的时机或可能性、我们在获得批准后将候选产品商业化的努力是否成功、我们为临床活动以及获得批准后用于商业用途的候选产品的能力、我们能够确立和维持的涵盖技术平台的知识产权的保护范围、我们获得未来融资、市场和其他条件以及我们的年度报告中确定的条件的能力10-K表格及随后的10-Q表季度报告，标题为 “风险因素”，以及公司定期向美国证券交易委员会提交的其他文件。我们敦促读者审查这些风险因素，不要依赖任何前瞻性陈述行事，因为实际结果可能与我们的前瞻性陈述所设想的结果有所不同。除非法律要求，否则Phio不承诺更新前瞻性陈述以反映本新闻稿发布之日后发生的观点、事件或情况的变化。
Contact:
Phio Pharmaceuticals Corp.
ir@phiopharma.com
联系人：
菲奥制药公司
ir@phiopharma.com
PR Contact
Michael Adams
Bridge View Media
adams@bridgeviewmedia.com
公关联系人
迈克·亚当斯
桥景媒体
adams@bridgeviewmedia.com
译文内容由第三方软件翻译。